How Do We Apply Evidence Supporting TROP2 Directed ADCs to the Metastatic TNBC Treatment Paradigm?
Sara M. Tolaney MD, MPH
PeerSara A. Hurvitz, MD, FACP
PeerSara A. Hurvitz, MD, FACP
PeerSara M. Tolaney MD, MPH
PeerSara A. Hurvitz, MD, FACP
PeerSara M. Tolaney MD, MPH
PeerHow Do Brain Metastases Affect Your Choice of Systemic Treatment in a Patient with HR+/HER2-low MBC?
Sarah Sammons, MD
PeerWho Is the Best Candidate for Sequencing Sacituzumab Govitecan Before T-DXd in HR+ Breast Cancer?
Sarah Sammons, MD
Peer